Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PARG | Q86W56 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24534990 | 0.90 | PIK3CD (0.51) | NPC1RAB9APIK3CDKDM4ESMN1; SMN2 | |
| SCHEMBL20329218 | 0.83 | KDM4E (0.41) | NPC1RAB9ANAAAKDM4ESMN1; SMN2 | |
| SCHEMBL2824281 | 0.83 | MAPK1 (0.46) | NPC1RAB9ANAAAMAPK1TSHR | |
| SCHEMBL3584051 | 0.81 | PLA2G10 (0.42) | NPC1RAB9APIK3CDNAAAMAPK1 | |
| SCHEMBL11983582 | 0.79 | PIK3CD (0.42) | NPC1RAB9APIK3CDNAAAMAPK1 | |
| SCHEMBL12892358 | 0.78 | MEN1 (0.46) | NPC1RAB9ANAAAMAPK1SMN1; SMN2 | |
| SCHEMBL2058981 | 0.78 | PIK3CD (0.46) | NPC1RAB9APIK3CDNAAAMAPK1 | |
| SCHEMBL908640 | 0.77 | HSD17B10 (0.41) | PIK3CDNAAAMAPK1KDM4EALDH1A1 | |
| SCHEMBL13096630 | 0.76 | NAAA (0.42) | NPC1RAB9APIK3CDNAAAMAPK1 | |
| SCHEMBL24879866 | 0.76 | SMN1; SMN2 (0.41) | KDM4ESMN1; SMN2TSHRALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239461-A1 | CHEMICAL PROCESS FOR MANUFACTURING MONOBACTAM ANTIBIOTIC AND INTERMEDIATES THEREOF | SUZHOU NOVARTIS PHARMA TECHNOLOGY CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
| US-5922881-A | Heterocyclic imino derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239461-A1 | CHEMICAL PROCESS FOR MANUFACTURING MONOBACTAM ANTIBIOTIC AND INTERMEDIATES THEREOF | SRR, DCXR, JMJD6 | NPC1 4530/4885RAB9A 2880/4885PIK3CD 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.